Case Reports in Medicine

Case Reports in Medicine / 2009 / Article

Case Report | Open Access

Volume 2009 |Article ID 471623 | 2 pages | https://doi.org/10.1155/2009/471623

Anti-E Alloimmunization: A Rare Cause of Severe Fetal Hemolytic Disease Resulting in Pregnancy Loss

Academic Editor: Terence T. Lao
Received01 Aug 2009
Accepted30 Dec 2009
Published09 Mar 2010

Abstract

We report a case of severe intrauterine hemolysis caused by sole anti-E alloimmunization. A 36-year-old multipara woman presented with hydrops fetalis at 27 weeks of gestation. She had a history of previous neonatal death. In this pregnancy, she was found to have very high titer of anti-E antibody. Ultrasonography detected marked skin edema, cardiomegaly, hepatosplenomegaly, pleural effusion, ascites, placentomegaly, and polyhydramnios. The Doppler peak systolic velocity in the middle cerebral artery was 0.8 m/s, indicating severe fetal anemia. Multiple intrauterine transfusions for the anemic fetus were administered. However, persistent severe fetal anemia and placentomegaly caused poor neonatal death and mirror syndrome in the mother. Uncommon red blood cell alloimmunization has to be watched for early in any population, especially in a woman with a history of unexplained perinatal loss.

1. Introduction

Antibodies with anti-E specificity are detected in 14–20% of pregnant women and it is one of the most common non-D Rhesus (Rh) antibody in the pathogenesis of neonatal hemolytic disease [1, 2]. However, anti-E is rarely associated with severe hemolytic anemia in the fetus [3, 4]. We report an unusual case of severe intrauterine hemolysis due to anti-E alloimmunization.

2. Case Presentation

A 36-year-old woman, G5P2AA1, was referred to our clinic at 27 weeks gestation due to the presence of hydrops fetalis. Antenatal examination at outside hospital is noncontributory for any hydrops fetalis. She had two previous cesarean sections without history of blood transfusion. The first baby was a term live-born. The second baby was born at 36 weeks gestation died in a few days after birth of unknown neonatal hepatomegaly only 3 years ago. Sonography of the fetus revealed marked skin edema, cardiomegaly, hepatosplenomegaly, pleural effusion, ascites, placentomegaly, and polyhydramnios. Doppler peak systolic velocity (PSV) in the middle cerebral artery (MCA) was 0.8 m/s (>2.0 multiples of median) (MoM), indicating severe fetal anemia (Figure 1). Studies on karyotype, thalassemia, Parvovirus B19, cytomegalovirus, Toxoplasmosis, and antinuclear antibodies were all normal. Both parents had O and D+ blood type. Indirect Coombs’ test was positive and high titer of anti-E antibodies with antihuman globulin titers of 1  :  1024 was noted in the maternal blood. Rh typing of the mother was D( ) E( ) c( ) C( ) e( ). Severe fetal anemia was confirmed by umbilical cord blood sampling with hemoglobin (Hb) level of 2.1 g/dL and hematocrit of 6.1%. The phenotype of fetal red blood cells (RBCs) was O, D ( ) E( ) c( ) C( ) e( ) and strong positive in direct Coombs’ test (++++). Three times of 20 mL each in every week antenatal transfusions of irradiated Group O, D+ packed RBCs were administered between 28 and 30 weeks of gestation. Fetal anemia persisted between Hb levels between 3-4 g/dL with no improvement of hydrops and Doppler flow studies. She developed preeclampsia with elevated blood pressure and general edema. Cesarean section was performed at 31 weeks gestation after steroid administration for the mother who had twice section, delivering a 2000 g male baby with Apgar scores of 2 and 3 at 1 and 5 minutes, respectively. The placenta was bulky and grossly edematous weighing 1300 g. Even with multiple blood transfusions, the newborn succumbed in 2 days. Autopsy was declined.

3. Discussion

Anti-E alloimmunization can cause fetal anemia, and the incidence could be underestimated [5]. Only a few reports of pregnancy loss due to anti-E were described [4, 6]. Unlike anti-D alloimmunization, anti-E titer is less sensitive in detecting severity of hemolysis in the subsequent pregnancy. Therefore, high level of suspicion and early recognition of these cases is crucial even with low titers. A critical titer of 1  :  16 has been considered in anti-E alloimmunization [4]. Joy et al. reported that six of the 16 fetuses with maternal titer greater than 1  :  16 had fetal Hb less than 10 g/dL. Two fetal hydrops resulted in perinatal death despite intrauterine treatment. Extremely elevated titer coupled with very severe fetal anemia as in this present study is scarce [4, 6].

Using a cut-off of 1.5 MoM in the MCA of PSV Doppler studies, 100% sensitivity in the prediction of moderate to severe fetal anemia was reported [7]. If MCA PSV is added, fetal anemia is treatable with favorable outcome of over 90% before hydrops [8]. Fetal hydrops combined with very low cord blood Hb (2.1 g/dL) is a late and ominous presentation of hemolytic disease. Encountering this adverse clinical setting, receiving blood transfusions in our case was in vain.

An uncommon consequence of fetal hydrops that will worsen the condition is the development of maternal mirror syndrome. The trigger of rapid body weight gain, hydramnios, elevated blood pressure, and general edema in mirror syndrome may be derived from a compromised fetus or placenta. Immediate delivery should be performed to avoid maternal morbidity.

In conclusion, we advocate that in D women who had previous unexplained fetal loss (fetal hydrops), screening of maternal serum alloantibodies against RBCs is important in the early trimesters of pregnancy, followed by regular Doppler studies and treatment strategies if alloimmune cause of hemolysis is identified.

References

  1. C. K. Lee, E. S. K. Ma, M. Tang, C. C. K. Lam, C. K. Lin, and L. C. Chan, “Prevalence and specificity of clinically significant red cell alloantibodies in Chinese women during pregnancy—a review of cases from 1997 to 2001,” Transfusion Medicine, vol. 13, no. 4, pp. 227–231, 2003. View at: Publisher Site | Google Scholar
  2. O. Geifman-Holtzman, M. Wojtowycz, E. Kosmas, and R. Artal, “Female alloimmunization with antibodies known to cause hemolytic disease,” Obstetrics and Gynecology, vol. 89, no. 2, pp. 272–275, 1997. View at: Publisher Site | Google Scholar
  3. W. W. K. To, S.-N. Ho, and K. M. Mok, “Anti-E alloimmunizatio in pregnancy: management dilemmas,” Journal of Obstetrics and Gynaecology Research, vol. 29, no. 1, pp. 45–48, 2003. View at: Publisher Site | Google Scholar
  4. S. D. Joy, K. Q. Rossi, D. Krugh, and R. W. O'Shaughnessy, “Management of pregnancies complicated by anti-E alloimmunization,” Obstetrics and Gynecology, vol. 105, no. 1, pp. 24–28, 2005. View at: Publisher Site | Google Scholar
  5. I. Z. MacKenzie, P. J. Bowell, M. Selinger, R. M. Hussey, and C. A. Clarke, “Deaths from haemolytic disease of the newborn,” British Medical Journal, vol. 304, no. 6835, pp. 1175–1176, 1992. View at: Google Scholar
  6. P. L. Strohm, J. D. Iams, and M. S. Kennedy, “Hemolytic disease of the newborn from anti-E. A case report,” Journal of Reproductive Medicine for the Obstetrician and Gynecologist, vol. 33, no. 4, pp. 404–406, 1988. View at: Google Scholar
  7. G. Mari, R. L. Deter, R. L. Carpenter et al., “Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization,” The New England Journal of Medicine, vol. 342, no. 1, pp. 9–14, 2000. View at: Publisher Site | Google Scholar
  8. P. Moran, S. C. Robson, and M. M. Reid, “Anti-E in pregnancy,” British Journal of Obstetrics and Gynaecology, vol. 107, no. 11, pp. 1436–1438, 2000. View at: Google Scholar

Copyright © 2009 An-Shine Chao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

21861 Views | 773 Downloads | 2 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.